Chinese Journal of Dermatology ›› 2023, Vol. 56 ›› Issue (5): 402-409.doi: 10.35541/cjd.20220909
• Guidelines and Consensus • Previous Articles Next Articles
Writing Committee Expert Group on “Treatment of mycosis fungoides: a Chinese expert consensus (2023)”
Received:
2022-12-21
Revised:
2023-03-09
Online:
2023-05-15
Published:
2023-05-04
Contact:
Shen Xiaoyan; Zheng Jie
E-mail:shenxiaoyan2018@139.com; jie-zheng2001@126.com
Writing Committee Expert Group on “Treatment of mycosis fungoides: a Chinese expert consensus ()”. Treatment of mycosis fungoides: a Chinese expert consensus (2023)[J]. Chinese Journal of Dermatology, 2023, 56(5): 402-409.doi:10.35541/cjd.20220909
[1] | Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO⁃EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703⁃1714[J]. Blood, 2019,134(13):1112. doi: 10.1182/blood.2019002852. |
[2] | Kaufman AE, Patel K, Goyal K, et al. Mycosis fungoides: developments in incidence, treatment and survival[J]. J Eur Acad Dermatol Venereol, 2020,34(10):2288⁃2294. doi: 10.1111/ jdv.16325. |
[3] | Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome ⁃ Update 2017[J]. Eur J Cancer, 2017,77:57⁃74. doi: 10.1016/j.ejca.2017. 02.027. |
[4] | Gilson D, Whittaker SJ, Child FJ, et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018[J]. Br J Dermatol, 2019,180(3):496⁃526. doi: 10.1111/bjd.17240. |
[5] | National Comprehensive Cancer Network. 2022 NCCN Guidelines Primary Cutaneous Lymphomas[EB/OL]. https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf. |
[6] | Phyo ZH, Shanbhag S, Rozati S. Update on biology of cutaneous T⁃cell lymphoma[J]. Front Oncol, 2020,10:765. doi: 10.3389/fonc.2020.00765. |
[7] | Krejsgaard T, Litvinov IV, Wang Y, et al. Elucidating the role of interleukin⁃17F in cutaneous T⁃cell lymphoma[J]. Blood, 2013,122(6):943⁃950. doi: 10.1182/blood⁃2013⁃01⁃480889. |
[8] | Hodak E, Geskin L, Guenova E, et al. Real⁃life barriers to diagnosis of early mycosis fungoides: an international expert panel discussion[J]. Am J Clin Dermatol, 2023,24(1):5⁃14. doi: 10.1007/s40257⁃022⁃00732⁃w. |
[9] | Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides[J]. J Am Acad Dermatol, 2005,53(6):1053⁃1063. doi: 10.1016/j.jaad.2005.08.057. |
[10] | Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)[J]. Blood, 2007,110(6):1713⁃1722. doi: 10.1182/blood⁃2007⁃03⁃055749. |
[11] | Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer[J]. J Clin Oncol, 2011,29(18):2598⁃2607. doi: 10.1200/JCO. 2010.32.0630. |
[12] | Larocca C, Kupper T. Mycosis fungoides and Sézary syndrome: an update[J]. Hematol Oncol Clin North Am, 2019,33(1):103⁃120. doi: 10.1016/j.hoc.2018.09.001. |
[13] | Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model[J]. J Clin Oncol, 2015,33(32):3766⁃3773. doi: 10.1200/JCO.2015.61.7142. |
[14] | OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence[EB/OL]. http://www.cebm.net/index.aspx?oZ5653. |
[15] | Zackheim HS, Kashani⁃Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients[J]. Arch Dermatol, 1998,134(8):949⁃954. doi: 10.1001/archderm.134.8. 949. |
[16] | Kartan S, Shalabi D, O′Donnell M, et al. Response to topical corticosteroid monotherapy in mycosis fungoides[J]. J Am Acad Dermatol, 2021,84(3):615⁃623. doi: 10.1016/j.jaad.2020.05.043. |
[17] | Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T⁃cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides[J]. JAMA Dermatol, 2013,149(1):25⁃32. doi: 10.1001/2013.jamadermatol.541. |
[18] | Kim EJ, Guitart J, Querfeld C, et al. The PROVe study: US real⁃world experience with chlormethine/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T⁃cell lymphoma[J]. Am J Clin Dermatol, 2021,22(3):407⁃414. doi: 10.1007/s40257⁃021⁃00591⁃x. |
[19] | Correia E, Krishnasamy S, Suriano JG, et al. Response to chlormethine/mechlorethamine gel maintenance treatment regimen in patients with mycosis fungoides: a single⁃center retrospective study[J]. Clin Lymphoma Myeloma Leuk, 2022,22(8):581⁃588. doi: 10.1016/j.clml.2022.02.002. |
[20] | Heald P, Mehlmauer M, Martin AG, et al. Topical bexarotene therapy for patients with refractory or persistent early⁃stage cutaneous T⁃cell lymphoma: results of the phase Ⅲ clinical trial[J]. J Am Acad Dermatol, 2003,49(5):801⁃815. doi: 10.1016/s0190⁃9622(03)01475⁃0. |
[21] | Apisarnthanarax N, Talpur R, Ward S, et al. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open⁃label pilot study[J]. J Am Acad Dermatol, 2004,50(4):600⁃607. doi: 10. 1016/j.jaad.2003.09.005. |
[22] | Shipman AR, Scarisbrick J. New treatment options for mycosis fungoides[J]. Indian J Dermatol, 2016,61(1):119. doi: 10. 4103/0019⁃5154.174085. |
[23] | Gilchrest BA, Parrish JA, Tanenbaum L, et al. Oral methoxsalen photochemotherapy of mycosis fungoides[J]. Cancer, 1976,38(2):683⁃689. doi: 10.1002/1097⁃0142(197608)38:2<683::aid⁃cncr2820380210>3.0.co;2⁃v. |
[24] | Hofer A, Cerroni L, Kerl H, et al. Narrowband (311⁃nm) UV⁃B therapy for small plaque parapsoriasis and early⁃stage mycosis fungoides[J]. Arch Dermatol, 1999,135(11):1377⁃1380. doi: 10.1001/archderm.135.11.1377. |
[25] | Phan K, Ramachandran V, Fassihi H, et al. Comparison of narrowband UV⁃B with psoralen⁃UV⁃A phototherapy for patients with early⁃stage mycosis fungoides: a systematic review and meta⁃analysis[J]. JAMA Dermatol, 2019,155(3):335⁃341. doi: 10.1001/jamadermatol.2018.5204. |
[26] | Olsen EA, Hodak E, Anderson T, et al. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium[J]. J Am Acad Dermatol, 2016,74(1):27⁃58. doi: 10.1016/j.jaad.2015.09.033. |
[27] | Pavlotsky F, Hodak E, Ben Amitay D, et al. Role of bath psoralen plus ultraviolet A in early⁃stage mycosis fungoides[J]. J Am Acad Dermatol, 2014,71(3):536⁃541. doi: 10.1016/j.jaad. 2014.04.011. |
[28] | Trovato E, Pellegrino M, Filippi F, et al. Clinical and histological evaluation in patients with mycosis fungoides treated with UVA1[J]. G Ital Dermatol Venereol, 2020,155(3):306⁃311. doi: 10.23736/S0392⁃0488.18.05867⁃4. |
[29] | Deaver D, Cauthen A, Cohen G, et al. Excimer laser in the treatment of mycosis fungoides[J]. J Am Acad Dermatol, 2014,70(6):1058⁃1060. doi: 10.1016/j.jaad.2014.01.915. |
[30] | Xue J, Liu C, Liu Y. Photodynamic therapy as an alternative treatment for relapsed or refractory mycosis fungoides: a systemic review[J]. Photodiagnosis Photodyn Ther, 2017,17:87⁃91. doi: 10.1016/j.pdpdt.2016.11.010. |
[31] | Vieyra⁃Garcia P, Fink⁃Puches R, Porkert S, et al. Evaluation of low⁃dose, low⁃frequency oral psoralen⁃UV⁃A treatment with or without maintenance on early⁃stage mycosis fungoides: a randomized clinical trial[J]. JAMA Dermatol, 2019,155(5):538⁃547. doi: 10.1001/jamadermatol.2018.5905. |
[32] | Moraes FY, Carvalho Hde A, Hanna SA, et al. Literature review of clinical results of total skin electron irradiation (TSEBT) of mycosis fungoides in adults[J]. Rep Pract Oncol Radiother, 2014,19(2):92⁃98. doi: 10.1016/j.rpor.2013.08.003. |
[33] | Jones GW, Kacinski BM, Wilson LD, et al. Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group[J]. J Am Acad Dermatol, 2002,47(3):364⁃370. doi: 10.1067/mjd.2002. 123482. |
[34] | Song A, Gochoco A, Zhan T, et al. A prospective cohort study of condensed low⁃dose total skin electron beam therapy for mycosis fungoides: reduction of disease burden and improvement in quality of life[J]. J Am Acad Dermatol, 2020,83(1):78⁃85. doi: 10.1016/j.jaad.2020.01.046. |
[35] | Specht L, Dabaja B, Illidge T, et al. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group[J]. Int J Radiat Oncol Biol Phys, 2015,92(1):32⁃39. doi: 10.1016/j.ijrobp. 2015.01.008. |
[36] | Zhang C, Duvic M. Treatment of cutaneous T⁃cell lymphoma with retinoids[J]. Dermatol Ther, 2006,19(5):264⁃271. doi: 10. 1111/j.1529⁃8019.2006.00083.x. |
[37] | Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early⁃stage cutaneous T⁃cell lymphoma[J]. Arch Dermatol, 2001,137(5):581⁃593. doi: 10⁃1001/pubs.Arch Dermatol.⁃ISSN⁃0003⁃987x⁃137⁃5⁃dst0039. |
[38] | Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced⁃stage cutaneous T⁃cell lymphoma: multinational phase Ⅱ -Ⅲ trial results[J]. J Clin Oncol, 2001,19(9):2456⁃2471. doi: 10.1200/JCO.2001.19.9.2456. |
[39] | Whittaker S, Ortiz P, Dummer R, et al. Efficacy and safety of bexarotene combined with psoralen⁃ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB⁃IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase Ⅲ randomized clinical trial (NCT00056056)[J]. Br J Dermatol, 2012,167(3):678⁃687. doi: 10.1111/j.1365⁃2133.2012.11156.x. |
[40] | Ginsburg E, Hennessy K, Mhaskar R, et al. Treatment of early⁃stage mycosis fungoides with oral bexarotene and phototherapy: a systematic review and meta⁃analysis[J]. Dermatol Ther, 2022,35(5):e15418. doi: 10.1111/dth.15418. |
[41] | Bunn PA Jr, Foon KA, Ihde DC, et al. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T⁃cell lymphomas[J]. Ann Intern Med, 1984,101(4):484⁃487. doi: 10.7326/0003⁃4819⁃101⁃4⁃484. |
[42] | Spaccarelli N, Rook AH. The Use of Interferons in the treatment of cutaneous T⁃cell lymphoma[J]. Dermatol Clin, 2015,33(4):731⁃745. doi: 10.1016/j.det.2015.05.008. |
[43] | Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon ⁃2a plus acitretin versus interferon ⁃2a plus PUVA in patients with cutaneous T⁃cell lymphoma stages Ⅰ and Ⅱ[J]. Blood, 1998,92(10):3578⁃3581. doi: 10.1182/blood.V92.10.3578. |
[44] | Aviles A, Neri N, Fernandez⁃Diez J, et al. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T⁃cell lymphoma[J]. Hematology, 2015,20(9):538⁃542. doi: 10.1179/1607845415Y. 0000000002. |
[45] | Alenezi F, Girard C, Bessis D, et al. Benefit/risk ratio of low⁃dose methotrexate in cutaneous lesions of mycosis fungoides and Sézary syndrome[J]. Acta Derm Venereol, 2021,101(2):adv00384. doi: 10.2340/00015555⁃3719. |
[46] | Tirelli U, Errante D, van Glabbeke M, et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate⁃grade and high⁃grade non⁃Hodgkin′s lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol, 1998,16(1):27⁃34. doi: 10.1200/JCO.1998.16.1.27. |
[47] | Dummer R, Quaglino P, Becker JC, et al. Prospective international multicenter phase Ⅱ trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012[J]. J Clin Oncol, 2012,30(33):4091⁃4097. doi: 10.1200/JCO.2011.39.8065. |
[48] | Knobler R, Arenberger P, Arun A, et al. European dermatology forum ⁃ updated guidelines on the use of extracorporeal photopheresis 2020 ⁃ part 1[J]. J Eur Acad Dermatol Venereol, 2020,34(12):2693⁃2716. doi: 10.1111/jdv.16890. |
[49] | Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors[J]. Nat Rev Drug Discov, 2006,5(9):769⁃784. doi: 10.1038/nrd2133. |
[50] | Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T⁃cell lymphoma (CTCL)[J]. Blood, 2007,109(1):31⁃39. doi: 10.1182/blood⁃2006⁃06⁃025999. |
[51] | Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T⁃cell lymphoma[J]. J Clin Oncol, 2010,28(29):4485⁃4491. doi: 10.1200/JCO.2010.28.9066. |
[52] | Foss F, Advani R, Duvic M, et al. A Phase Ⅱ trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T⁃cell lymphoma[J]. Br J Haematol, 2015,168(6):811⁃819. doi: 10.1111/bjh.13222. |
[53] | Shi Y, Jia B, Xu W, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real⁃world study in China[J]. J Hematol Oncol, 2017,10(1):69. doi: 10.1186/s13045⁃017⁃0439⁃6. |
[54] | Kim YH, Bagot M, Pinter⁃Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T⁃cell lymphoma (MAVORIC): an international, open⁃label, randomised, controlled phase 3 trial[J]. Lancet Oncol, 2018,19(9):1192⁃1204. doi: 10.1016/S1470⁃2045(18)30379⁃6. |
[55] | Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician′s choice in cutaneous T⁃cell lymphoma: final data[J]. Blood Adv, 2021,5(23):5098⁃5106. doi: 10.1182/bloodadvances.2021004710. |
[56] | Kim YH, Prince HM, Whittaker S, et al. Response to brentuximab vedotin versus physician′s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub⁃analysis[J]. Eur J Cancer, 2021,148:411⁃421. doi: 10.1016/j.ejca.2021.01.054. |
[57] | Domingo⁃Domenech E, Duarte RF, Boumedil A, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation[J]. Bone Marrow Transplant, 2021,56(6):1391⁃1401. doi: 10.1038/s41409⁃020⁃01197⁃3. |
[58] | Iqbal M, Reljic T, Ayala E, et al. Efficacy of allogeneic hematopoietic cell transplantation in cutaneous T cell lymphoma: results of a systematic review and meta⁃analysis[J]. Biol Blood Marrow Transplant, 2020,26(1):76⁃82. doi: 10.1016/j.bbmt.2019.08.019. |
[59] | Dumont M, Peffault de Latour R, Ram⁃Wolff C, et al. Allogeneic hematopoietic stem cell transplantation in cutaneous T⁃cell lymphomas[J]. Cancers (Basel), 2020,12(10). doi: 10.3390/cancers12102856. |
[1] | Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China (2023 edition) [J]. Chinese Journal of Dermatology, 2023, 56(7): 573-625. |
[2] | Liang Yunsheng, Li Zhanhong, Wu Yibei. Progress in the treatment of chronic spontaneous urticaria: insights from the changes in the understanding of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(6): 552-558. |
[3] | Yang Nali, Xu Qiuyang, Wu Hanwen, Ye Yahui, Zhu Jiling, Liu Jingjing, Li Zhiming. Efficacy and safety of omalizumab in the treatment of chronic urticaria: a retrospective analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 518-524. |
[4] | Su Chang, Sui Xiuli, Liu Ruiling, Cao Yiqun, Jiang Hong, Yan Cairong, Wang Huiping, Qi Yuqing. Omalizumab for the treatment of 74 patients with chronic spontaneous urticaria accompanied by other allergic diseases: a clinical analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 512-517. |
[5] | Wang Xin, Liu Lijuan, Li Linfeng. Clinical features of chronic spontaneous urticaria in China: results from a hospital-based multicenter epidemiological survey [J]. Chinese Journal of Dermatology, 2023, 56(6): 525-530. |
[6] | Li Liqiao, Peng Cong, Chen Xiang, Li Jie. Efficacy of omalizumab in the treatment of chronic urticaria patients with poor response to antihistamines: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(6): 504-511. |
[7] | Chen Qiquan, Yang Xianjie, Gu Heng, Xu Jinhua, Hao Fei, Yao Xu, Song Zhiqiang. Construction of “Expert consensus on diagnosis and treatment of chronic inducible urticaria in China (2023)” based on the Delphi method [J]. Chinese Journal of Dermatology, 2023, 56(6): 534-539. |
[8] | Immunology Group, Chinese Society of Dermatology. Expert consensus on diagnosis and treatment of chronic inducible urticaria in China (2023) [J]. Chinese Journal of Dermatology, 2023, 56(6): 479-488. |
[9] | Wang Junxia, Guo Weinan, Chen Hui, Hao Junfeng, Li Bing, Wei Jingyi, Zhao Tao. Efficacy of autologous fat grafting in the treatment of 40 cases of stable linear scleroderma: a retrospective analysis [J]. Chinese Journal of Dermatology, 2023, 0(3): 20210866-e20210866. |
[10] | Guo Weinan, Wang Junxia, Chen Hui, Hao Junfeng, Li Bing, Wei Jingyi, Zhao Tao. Clinical efficacy of autologous adipose-derived stem cell gel grafting in the treatment of depressed acne scars [J]. Chinese Journal of Dermatology, 2023, 0(3): 20210867-e20210867. |
[11] | Wang Xingwang, Yang Huilan. Reasonable selection of antiviral agents for herpes zoster [J]. Chinese Journal of Dermatology, 2023, 56(3): 262-265. |
[12] | Zhou Jian, Yu Chen, Wang Gang. Clinical efficacy and safety of secukinumab in the treatment of 13 cases of refractory localized pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 247-251. |
[13] | Hu Kun, Yang Jing, Wang Qiaolin, Chen Junchen, Zhang Mi, Zhu Wu, Zhang Bin, Dou Guanshen, Wendong Chen, Kuang Yehong. Real-world short-term treatment effects of Ixekizumab in Chinese patients with psoriasis: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(3): 210-215. |
[14] | Wan Li, Hu Bin, Luo Hongyu, Fang Meizhen, Han Lijuan, Chen Qiang, Zhou Xiaoyong, Chen Liuqing, Chen Jinbo. Clinical characteristics and treatment of eight cases of pemphigus/bullous pemphigoid complicated by herpes simplex virus infection [J]. Chinese Journal of Dermatology, 2023, 56(3): 229-233. |
[15] | Zhang Hongyan, Li Li, Wang Mingxia, Dong Yinmao, Meng Hong, Yi Fan. Role of probiotics in the treatment of acne [J]. Chinese Journal of Dermatology, 2023, 56(3): 283-285. |
|